U.S. markets closed

XBiotech Inc. (XBIT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
4.3600-0.2000 (-4.39%)
At close: 03:59PM EDT

XBiotech Inc.

5217 Winnebago Lane
Austin, TX 78744
United States
512 386 2900

Full Time Employees84

Key Executives

NameTitlePayExercisedYear Born
Mr. John SimardFounder, Pres, CEO & Chairman4.67MN/A1962
Dr. Sushma Shivaswamy Ph.D.Chief Scientific Officer381.24kN/A1978
Ms. Angela HuDirector of Fin., Principal Financial & Accounting Officer and Financial ControllerN/AN/A1984
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Corporate Governance

XBiotech Inc.’s ISS Governance QualityScore as of September 1, 2023 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.